Table 5.

Responding population of dogs treated with ABT-510

BreedTumor histologyTNM stageResponseResponse duration (d)
Golden retrieverNHLIVaCR240
DobermanOral fibrosarcomaT2N0M0PR970
Norfolk terrierOral fibrosarcomaT2N0M0CR>450
Standard poodleHemangiosarcomaT(sx)N0M1PR530
Golden retrieverLingual/labial hemangiosarcomaT2N0M1PR570
Labrador retrieverCutaneous T-cell lymphomaCutaneousPR75
DalmatianHemangiopericytomaT2N0M0CR>450
Labrador retriever mixNHLIIIaPR>150
Labrador retriever mixMulticentric cutaneous plasmacytomasT2N0M1PR>120
Labrador retriever mixCutaneous B-cell lymphomaCutaneousSD140
Shepherd mixMetastatic insulinomaT(sx)N0M1SD240
Scottish terrierThyroid adenocarcinomaT2N0M0SD150
DachshundNHLIIIaSD62
Labrador retriever mixTransitional cell carcinomaT2N0M0SD420
Shetland sheepdogFibrosarcomaT(sx)N0M1SD453
Springer spanielPapillary carcinoma, nasalT3bN0M0SD120
Labrador retriever mixCutaneous plasmacytomaT2N0M1SD90
MalteseTransitional cell carcinomaT2N0M0SD270
Shepherd mixThyroid adenocarcinomaT3N0M0SD>210
Shepherd mixThyroid carcinomaT2bN0M0SD>270
Australian cattle dog mixRhabdomyosarcomaT3N0M0SD>120
PuliAnaplastic transitional cell carcinomaT2N0M0SD>90
Fox terrierProstatic adenocarcinomaT2N0M0SD>120